Seeking Alpha
25 Jun 2026, 05:23 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Veligrotug has a set FDA PDUFA date of June 30, 2026, following pivotal Phase 3 data in active and chronic TED. — A binary FDA decision on a pivotal Phase 3 asset is the primary driver of valuation for late-stage biotech companies.
+0.80Viridian plans a BLA submission for Elegrobart, a subcutaneous follow-on asset, in Q1 2027. — A subcutaneous delivery method expands the total addressable market and creates long-term competitive durability.
+0.40Which stocks this story touches
The company is transitioning to a commercial player with positive Phase 3 data and upcoming FDA milestones.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
8h ago
